Literature DB >> 24580050

Adenovirus-based vaccines for fighting infectious diseases and cancer: progress in the field.

Dragomira Majhen1, Hugo Calderon, Naresh Chandra, Carlos Alberto Fajardo, Anandi Rajan, Ramon Alemany, Jerome Custers.   

Abstract

The field of adenovirology is undergoing rapid change in response to increasing appreciation of the potential advantages of adenoviruses as the basis for new vaccines and as vectors for gene and cancer therapy. Substantial knowledge and understanding of adenoviruses at a molecular level has made their manipulation for use as vaccines and therapeutics relatively straightforward in comparison with other viral vectors. In this review we summarize the structure and life cycle of the adenovirus and focus on the use of adenovirus-based vectors in vaccines against infectious diseases and cancers. Strategies to overcome the problem of preexisting antiadenovirus immunity, which can hamper the immunogenicity of adenovirus-based vaccines, are discussed. When armed with tumor-associated antigens, replication-deficient and oncolytic adenoviruses can efficiently activate an antitumor immune response. We present concepts on how to use adenoviruses as therapeutic cancer vaccines and consider some of the strategies used to further improve antitumor immune responses. Studies that explore the prospect of adenoviruses as vaccines against infectious diseases and cancer are underway, and here we give an overview of the latest developments.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24580050     DOI: 10.1089/hum.2013.235

Source DB:  PubMed          Journal:  Hum Gene Ther        ISSN: 1043-0342            Impact factor:   5.695


  47 in total

1.  Novel chimpanzee adenovirus-vectored respiratory mucosal tuberculosis vaccine: overcoming local anti-human adenovirus immunity for potent TB protection.

Authors:  M Jeyanathan; N Thanthrige-Don; S Afkhami; R Lai; D Damjanovic; A Zganiacz; X Feng; X-D Yao; K L Rosenthal; M Fe Medina; J Gauldie; H C Ertl; Z Xing
Journal:  Mucosal Immunol       Date:  2015-04-15       Impact factor: 7.313

2.  Enzyme/Prodrug Systems for Cancer Gene Therapy.

Authors:  Obeid M Malekshah; Xuguang Chen; Alireza Nomani; Siddik Sarkar; Arash Hatefi
Journal:  Curr Pharmacol Rep       Date:  2016-10-19

3.  Trial watch: Naked and vectored DNA-based anticancer vaccines.

Authors:  Norma Bloy; Aitziber Buqué; Fernando Aranda; Francesca Castoldi; Alexander Eggermont; Isabelle Cremer; Catherine Sautès-Fridman; Jitka Fucikova; Jérôme Galon; Radek Spisek; Eric Tartour; Laurence Zitvogel; Guido Kroemer; Lorenzo Galluzzi
Journal:  Oncoimmunology       Date:  2015-04-02       Impact factor: 8.110

4.  Inclusion of the murine IgGκ signal peptide increases the cellular immunogenicity of a simian adenoviral vectored Plasmodium vivax multistage vaccine.

Authors:  Jairo A Fonseca; Jessica N McCaffery; Juan Caceres; Elena Kashentseva; Balwan Singh; Igor P Dmitriev; David T Curiel; Alberto Moreno
Journal:  Vaccine       Date:  2018-04-12       Impact factor: 3.641

Review 5.  51 years in of Chikungunya clinical vaccine development: A historical perspective.

Authors:  Arturo Reyes-Sandoval
Journal:  Hum Vaccin Immunother       Date:  2019-04-02       Impact factor: 3.452

6.  Adenovirus Serotype 5 Vaccination Results in Suboptimal CD4 T Helper 1 Responses in Mice.

Authors:  Junghwa Lee; Masao Hashimoto; Se Jin Im; Koichi Araki; Hyun-Tak Jin; Carl W Davis; Bogumila T Konieczny; Gregory A Spies; M Juliana McElrath; Rafi Ahmed
Journal:  J Virol       Date:  2017-02-14       Impact factor: 5.103

7.  Recent advances of oncolytic virus in cancer therapy.

Authors:  Moumita Mondal; Jingao Guo; Ping He; Dongming Zhou
Journal:  Hum Vaccin Immunother       Date:  2020-02-20       Impact factor: 3.452

8.  Pilot and Feasibility Trial Evaluating Immuno-Gene Therapy of Malignant Mesothelioma Using Intrapleural Delivery of Adenovirus-IFNα Combined with Chemotherapy.

Authors:  Daniel H Sterman; Evan Alley; James P Stevenson; Joseph Friedberg; Susan Metzger; Adri Recio; Edmund K Moon; Andrew R Haas; Anil Vachani; Sharyn I Katz; Jing Sun; Daniel F Heitjan; Wei-Ting Hwang; Leslie Litzky; Jennifer H Yearley; Kay See Tan; Emmanouil Papasavvas; Paul Kennedy; Luis J Montaner; Keith A Cengel; Charles B Simone; Melissa Culligan; Corey J Langer; Steven M Albelda
Journal:  Clin Cancer Res       Date:  2016-03-11       Impact factor: 12.531

9.  Antibody responses to prime-boost vaccination with an HIV-1 gp145 envelope protein and chimpanzee adenovirus vectors expressing HIV-1 gp140.

Authors:  Kristel L Emmer; Lindsay Wieczorek; Steven Tuyishime; Sebastian Molnar; Victoria R Polonis; Hildegund C J Ertl
Journal:  AIDS       Date:  2016-10-23       Impact factor: 4.177

10.  Impact of dynamin 2 on adenovirus nuclear entry.

Authors:  Ji Sun Lee; Ashrafali M Ismail; Jeong Yoon Lee; Xiaohong Zhou; Emma C Materne; James Chodosh; Jaya Rajaiya
Journal:  Virology       Date:  2019-01-10       Impact factor: 3.616

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.